

Laura Lupini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7253004/publications.pdf>

Version: 2024-02-01

32
papers

1,839
citations

394421

19
h-index

434195

31
g-index

33
all docs

33
docs citations

33
times ranked

3857
citing authors

#	ARTICLE	IF	CITATIONS
1	Oncogenic Role of <i>miR-483-3p</i> at the <i>IGF2/483</i> Locus. <i>Cancer Research</i> , 2010, 70, 3140-3149.	0.9	272
2	<i>miR-145</i> participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor- α in human breast cancer cells. <i>Cell Death and Differentiation</i> , 2010, 17, 246-254.	11.2	231
3	Downregulation of the Mitochondrial Calcium Uniporter by Cancer-Related <i>miR-25</i> . <i>Current Biology</i> , 2013, 23, 58-63.	3.9	198
4	Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. <i>Hepatology</i> , 2012, 56, 1025-1033.	7.3	150
5	MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. <i>Molecular Cancer</i> , 2010, 9, 123.	19.2	107
6	Absolute quantification of cell-free microRNAs in cancer patients. <i>Oncotarget</i> , 2015, 6, 14545-14555.	1.8	103
7	Circulating <i>miR-106b-3p</i> , <i>miR-101-3p</i> and <i>miR-1246</i> as diagnostic biomarkers of hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 15350-15364.	1.8	79
8	Quantification of Circulating miRNAs by Droplet Digital PCR: Comparison of EvaGreen- and TaqMan-Based Chemistries. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2638-2642.	2.5	78
9	In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI. <i>Blood</i> , 2017, 129, 3495-3498.	1.4	74
10	<i>miR-125b</i> targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression. <i>Molecular Cancer</i> , 2013, 12, 130.	19.2	73
11	Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients. <i>BMC Cancer</i> , 2015, 15, 808.	2.6	54
12	Mutated β -catenin evades a microRNA-dependent regulatory loop. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 4840-4845.	7.1	48
13	Over-expression of the <i>miR-483-3p</i> overcomes the <i>miR-145/TP53</i> pro-apoptotic loop in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 31361-31371.	1.8	45
14	<i>miR-221</i> affects multiple cancer pathways by modulating the level of hundreds messenger RNAs. <i>Frontiers in Genetics</i> , 2013, 4, 64.	2.3	42
15	Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 818-826.	2.8	37
16	Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations. <i>Journal of Hematology and Oncology</i> , 2016, 9, 88.	17.0	35
17	In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics. <i>British Journal of Haematology</i> , 2018, 181, 229-233.	2.5	34
18	Inhibiting the oncogenic <i>miR-221</i> by microRNA sponge: toward microRNA-based therapeutics for hepatocellular carcinoma. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2014, 7, 43-54.	0.6	34

#	ARTICLE	IF	CITATIONS
19	Circulating Non-coding RNA as Biomarkers in Colorectal Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016, 937, 171-181.	1.6	26
20	Molecular testing on bronchial washings for the diagnosis and predictive assessment of lung cancer. <i>Molecular Oncology</i> , 2020, 14, 2163-2175.	4.6	20
21	The Importance of microRNAs in RAS Oncogenic Activation in Human Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 988.	2.8	18
22	High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy. <i>Scientific Reports</i> , 2018, 8, 4371.	3.3	14
23	An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness. <i>Oncotarget</i> , 2017, 8, 28008-28020.	1.8	13
24	Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients. <i>Oncotarget</i> , 2014, 5, 140-149.	1.8	10
25	Circulating MicroRNA Quantification Using DNA-binding Dye Chemistry and Droplet Digital PCR. <i>Journal of Visualized Experiments</i> , 2016, , .	0.3	9
26	HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights. <i>Clinical Breast Cancer</i> , 2018, 18, e1133-e1139.	2.4	9
27	Molecular biomarkers predicting early development of endometrial carcinoma: A pilot study. <i>European Journal of Cancer Care</i> , 2019, 28, e13137.	1.5	9
28	A comprehensive approach for microbiota and health monitoring in mouse colonies using metagenomic shotgun sequencing. <i>Animal Microbiome</i> , 2021, 3, 53.	3.8	8
29	Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study. <i>Journal of Hematology and Oncology</i> , 2019, 12, 114.	17.0	5
30	MicroRNA Expression Profiling and Its Clinical Impact in Breast Cancer. , 2014, , 355-367.		2
31	<i>BCR/ABL1</i> -positive acute lymphoblastic leukemia relapsing as <i>BCR/ABL1</i> -negative acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 2065-2067.	1.3	1
32	Correction: Online Publication Dates for <i>Cancer Research</i> April 15, 2010 Articles. <i>Cancer Research</i> , 2010, 70, 4785-4786.	0.9	0